154 filings
DEFA14A
SCPH
scPharmaceuticals Inc
26 Apr 24
Additional proxy soliciting materials
4:26pm
DEF 14A
SCPH
scPharmaceuticals Inc
Definitive proxy
26 Apr 24
4:16pm
PRE 14A
SCPH
scPharmaceuticals Inc
12 Apr 24
Preliminary proxy
4:14pm
EFFECT
SCPH
scPharmaceuticals Inc
25 Mar 24
Notice of effectiveness
12:15am
424B5
SCPH
scPharmaceuticals Inc
22 Mar 24
Prospectus supplement for primary offering
4:48pm
S-8
zvcjoztz df
13 Mar 24
Registration of securities for employees
4:58pm
8-K
e5p6a fw42quha090
13 Mar 24
Generated full-year net FUROSCIX® revenue of $13.6 million, at the upper end of the range provided in January
4:08pm
8-K
q5ygz1vl yfnlezn
4 Jan 24
Gross-to-net (GTN) discount of approximately 18% from launch through the end of Q4
5:30pm
8-K
dvi11
8 Nov 23
Results of Operations and Financial Condition
4:05pm
8-K
qx4b9jnt
20 Sep 23
Entry into a Material Definitive Agreement
4:10pm
8-K
mxhay1w a3m7kgo
10 Aug 23
Results of Operations and Financial Condition
4:05pm
8-K
k53exqze3jc 6tkgoaat
8 Jun 23
Submission of Matters to a Vote of Security Holders
4:11pm
8-K
nd1efv832c1ijxvsv
7 Jun 23
Other Events
7:00am
8-K
blm18o7b p6yj5z8
10 May 23
Announced launch and commercial availability of FUROSCIX® on February 20th
4:08pm
DEFA14A
jx5xuvz 1j9x2jhrm03
27 Apr 23
Additional proxy soliciting materials
4:20pm